

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

49
gnd

In re application of:

BIRNSTIEL *et al.*

Appl. No. 08/380,200

Filed: January 30, 1995
(CPA filed August 28, 2001)

For: **New Protein-Polycation
Conjugates**

Art Unit: 1644

Examiner: Nolan, P.

Atty. Docket: 0652.1080001/EKS/PSC

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of the document is provided.

Document AL1 is in a foreign language. An English language abstract for document AL1 can be found on the front page of the document. Document AL1 appears to relate to peptides having immunological properties in common with those of the peptidic skeleton of peptides of HIV-2 family viruses, particularly the envelope glycoprotein of HIV-2, characterized in that they have also a peptidic structure in common with the peptidic skeleton of peptides of SIV, particularly the envelope glycoprotein of SIV.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 8/28/01
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

